CAPR
Capricor·NASDAQ
--
--(--)
--
--(--)
CAPR fundamentals
Capricor (CAPR) released its earnings on Mar 12, 2026: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.62 (YoY -287.50%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.62
-287.50%
Report date
Mar 12, 2026
CAPR Earnings Call Summary for Q4,2025
- Regulatory Breakthrough: FDA accepts BLA for Deramiocel with PDUFA date of August 22, 2026, following submission of full HOPE-3 trial data showing 91% disease progression slowing in cardiomyopathy and significant functional improvement in skeletal muscle.
- Manufacturing Scale-Up: San Diego facility expands to 2,500 patients/year by late 2027, positioning for global DMD market penetration.
- Financial Strength: $318 million cash runway supports operations into 2027, with potential PRV monetization adding $100-200 million.
- Pipeline Momentum: StealthX exosome platform advances toward 2027 IND filings, while Deramiocel expansion into Europe and Japan is underway.
- Clinical Impact: Deramiocel demonstrates ability to stabilize and improve both cardiac and skeletal muscle function in DMD, with no new safety signals after 800+ infusions.
EPS
Actual | -0.3 | -0.23 | -0.2 | -0.21 | -0.23 | -0.21 | -0.17 | -0.26 | -0.32 | -0.29 | -0.26 | -0.31 | -0.31 | -0.29 | -0.25 | -0.02 | -0.31 | -0.35 | -0.38 | -0.16 | -0.53 | -0.57 | -0.54 | -0.62 | |||||||||||
Forecast | -0.36 | -0.34 | -0.18 | -0.2 | -0.23 | -0.23 | -0.19 | -0.255 | -0.32 | -0.34 | -0.32 | -0.35 | -0.3033 | -0.09 | -0.1137 | -0.356 | -0.3583 | -0.17 | -0.3167 | -0.476 | -0.5467 | -0.509 | |||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +16.67% | +32.35% | -11.11% | -5.00% | 0.00% | +8.70% | +26.09% | -36.84% | 0.00% | -13.73% | +18.75% | +8.82% | +3.13% | +17.14% | +17.57% | +77.78% | -172.65% | +1.69% | -6.06% | +5.88% | -67.35% | -19.75% | +1.23% | -21.81% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 185.69K | 49.86K | 16.86K | 57.83K | 40.82K | 204.08K | 0 | 0 | 0 | 0 | 1.59M | 959.90K | 2.99M | 3.92M | 6.19M | 12.09M | 4.91M | 3.97M | 2.26M | 11.13M | 0 | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 210.00K | 210.00K | 210.00K | 210.00K | -- | 210.00K | 210.00K | 0 | -- | 390.00K | 420.00K | 10.00K | 1.00M | 3.00M | 3.15M | 10.60M | 9.70M | 4.58M | 4.28M | 11.52M | 3.16M | 1.42M | 600.00K | 525.00K |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11.57% | -76.26% | -91.97% | -72.46% | 0.00% | -2.82% | -100.00% | 0.00% | 0.00% | -100.00% | +278.94% | +9499.03% | +198.67% | +30.58% | +96.38% | +14.04% | -49.41% | -13.29% | -47.18% | -3.34% | -100.00% | -100.00% | -100.00% | -100.00% |
Earnings Call
You can ask Aime
What does Capricor do and what are its main business segments?What were the key takeaways from Capricor's earnings call?What were the key takeaways from Capricor’s earnings call?What is the revenue and EPS growth rate for Capricor year over year?What is Capricor's gross profit margin?What is the market's earnings forecast for Capricor next quarter?Did Capricor beat or miss consensus estimates last quarter?What guidance did Capricor's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
